🔗 Share this article

Given that the US proceeds with sweeping revisions to its immunization guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on Covid vaccines during the pandemic and has zeroed in on potential deaths after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Schedule

Health officials were set to reveal major revisions to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a major change that would place the US out of alignment with a large portion of the international standard with little proof for benefit. The planned update has been delayed until the next year.

In place of the top vaccines chief, Høeg is set to speak at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to lead the office this year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

Høeg has repeatedly called for halting some childhood immunization guidelines in the US so as to align more like Denmark, a society with universal health coverage and a population approximately the population of Wisconsin’s.

So far statements, she has persisted in emphasizing on immunizations – usually the domain of Dr. Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Qualifications

Høeg has no obvious track record in drug development, oversight or leadership, which has been standard for past leaders of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in managing a large organization. She is not an expert in drug approvals.”

Former directors of CBER would “understand regulatory frameworks and the research of drug development”, said Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who led CBER have had.”

The drug center has an immense range of responsibilities at the agency, the former commissioner pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic program approves a multitude of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and all of those need to be supervised,” she explained. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant management element to the position, which oversees over 5,000 personnel. “It’s a huge management job, if you do it right,” Woodcock said.

Official Statement and Contentious Programs

When asked about questions about Høeg’s credentials and whether this appointment signifies more teamwork among agency officials on immunizations, a representative responded that the “inquiries stem from inaccurate premises”.

“Her experience aligns with the responsibilities of her position,” the official explained, citing the time Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg inherits the agency head's recently launched priority voucher program, a disputed one-day therapy clearance system that allegedly worried her former heads. “By what process are these drugs being selected for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There is a lot of secrecy occurring at the agency right now.”

In general, he remarked, “the FDA seems to be moving towards more relaxed oversight of most medications, except for vaccines.”

Public Past Work on Immunizations

With immunizations, Dr. Høeg has a more documented, if concerning, history, some experts have noted. She released a analysis using unverified public submissions to estimate the incidence of heart inflammation after COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are riskier than they are.

Part of her “desired changes” for the incoming government featured changing rules for recently developed shots and halting “optional” immunizations, she said post-election on a audio program. At the FDA, Dr. Høeg has allegedly suggested preventing young men from getting COVID-19 vaccines.

“She is an thorough true believer who begins with her beliefs and reverse-engineers to fit the data in a highly deceptive, untruthful fashion,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg aligned with other skeptics, {like|